ALIQOPA ™ (copanlisib) for injection, for intravenous use

This specialty medication is manufactured abroad and is not registered or commercially marketed for retail sale in India. Access in India may require specific regulatory approvals or personal import permits as prescribed by relevant authorities. Under Named Patient Supply, SDP can serve you. To know the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.

ALIQOPA is a prescription medicine. ALIQOPA is used to treat follicular lymphoma.
INDICATIONS AND USAGE
ALIQOPA is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
DOSAGE FORMS & STRENGTHS
For injection: 60 mg as a lyophilized solid in single-dose vial for reconstitution.
Manufactured By: Bayer
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “ALIQOPA ™ (copanlisib) for injection” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category Lymphoma

ALIQOPA ™ (copanlisib) for injection, for intravenous use

Category Lymphoma

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

Description

Description

Copanlisib (trade name Aliqopa /ˌælɪˈkoʊpə/ AL-ih-KOH-pah; codenamed BAY 80-6946) is a drug which is approved by US FDA for the treatment of adult patients experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies

Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B-cells. It has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.